Erythritol as a Potential Causal Contributor to Cardiometabolic Disease: A Mendelian Randomization Study
Diabetes · 2024
DOI: 10.2337/db23-0330 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Rana Khafagy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University Health Network, and Banting & Best Diabetes Centre, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Coronary Artery Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Banting & Best Diabetes Centre, Canadian Institute of Health Research, Heart & Stroke Foundation of Canada.
Abstract (Originalsprache)
People with type 2 diabetes frequently use low-calorie sweeteners to manage glycemia and reduce caloric intake. Use of erythritol, a low-calorie sweetener, has increased recently. Higher circulating concentration associates with major cardiac events and metabolic disease in observational data, prompting some concern. As observational data may be prone to confounding and reverse causality, we undertook bidirectional Mendelian randomization (MR) to investigate potential causal associations between erythritol and coronary artery disease (CAD), BMI, waist-hip-ratio (WHR), and glycemic and renal traits in cohorts of European ancestry. Analyses were undertaken using instruments comprising genome-wide significant variants from three cohorts with erythritol measurement. Across instruments, we did not find supportive evidence that increased erythritol increases CAD (b = −0.033 ± 0.02, P = 0.14; b = 0.46 ± 0.37, P = 0.23). MR indicates erythritol may decrease BMI (b = −0.04 ± 0.018, P = 0.03; b = −0.04 ± 0.0085, P = 1.23 × 10−5; b = −0.083 ± 0.092, P = 0.036), with potential evidence from one instrument of increased BMI adjusted for WHR (b = 0.046 ± 0.022, P = 0.035). No evidence of causal association was found with other traits. In conclusion, we did not find supportive evidence from MR that erythritol increases cardiometabolic disease. These findings await confirmation in well-designed prospective studies. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, University Health Network, and Banting & Best Diabetes Centre, University of Toronto, Toronto, Canada.
- Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, Canada.
- Divisions of Epidemiology and Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
ORCID-Profile: Satya Dash
Förderung
- Banting & Best Diabetes Centre
- Canadian Institute of Health Research
- Heart & Stroke Foundation of Canada
Zitieren
APA
Khafagy, R., Paterson, A. D., & Dash, S. (2024). Erythritol as a Potential Causal Contributor to Cardiometabolic Disease: A Mendelian Randomization Study. Diabetes. https://doi.org/10.2337/db23-0330
Vancouver
Khafagy R, Paterson AD, Dash S. Erythritol as a Potential Causal Contributor to Cardiometabolic Disease: A Mendelian Randomization Study. Diabetes. 2024. doi:10.2337/db23-0330
BibTeX
@article{Khafagy2024,
author = {Khafagy, Rana and Paterson, Andrew D and Dash, Satya},
title = {Erythritol as a Potential Causal Contributor to Cardiometabolic Disease: A Mendelian Randomization Study},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db23-0330}
}
EUVIMED